Vrhovac R, Kusec R, Jaksić B
Department of Medicine, Clinical Hospital, Merkur, Zagreb, Croatia.
Int J Clin Pharmacol Ther Toxicol. 1993 May;31(5):241-52.
The article is a critical review of recent publications on myeloid hemopoietic growth factors. They are glycoproteins that regulate the proliferation and differentiation of hemopoietic progenitor cells and the function of mature blood cells. They are also named colony stimulating factors after the experimental technique that led to their discovery. Myeloid growth factors are: granulocyte macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), macrophage colony-stimulating factor (M-CSF) and interleukin-3. Studies of hemopoietic growth factors in the past years have revealed many potential beneficial effects, but some limitations as well. They have been proved effective, above all, in neutropenic conditions of different origin. A large number of clinical trials have shown their beneficial effect in myelosuppressive conditions after cytotoxic chemotherapy, in post-transplant period in bone marrow transplantation procedures and in neutropenic conditions as part of other clinical entities. Although a number of studies that should determine their clinical role more clearly is still underway, it seems certain that myeloid hemopoietic growth factors already have an important role in modern pharmacotherapy.
本文是对近期有关髓系造血生长因子的出版物的批判性综述。它们是调节造血祖细胞增殖和分化以及成熟血细胞功能的糖蛋白。根据导致其发现的实验技术，它们也被称为集落刺激因子。髓系生长因子包括：粒细胞巨噬细胞集落刺激因子（GM-CSF）、粒细胞集落刺激因子（G-CSF）、巨噬细胞集落刺激因子（M-CSF）和白细胞介素-3。过去几年对造血生长因子的研究揭示了许多潜在的有益作用，但也存在一些局限性。首先，它们已被证明在不同来源的中性粒细胞减少症中有效。大量临床试验表明，它们在细胞毒性化疗后的骨髓抑制状态、骨髓移植程序的移植后时期以及作为其他临床实体一部分的中性粒细胞减少症中具有有益作用。尽管仍有许多研究正在进行，以更清楚地确定它们的临床作用，但髓系造血生长因子似乎已经在现代药物治疗中发挥重要作用。
